Matinas BioPharma Holdings Inc (NASDAQ:MTNB) has been given a $9.00 price target by equities researchers at Roth Capital in a research report issued on Thursday. The firm currently has a “buy” rating on the stock.

Separately, Maxim Group restated a “buy” rating and issued a $6.00 target price on shares of Matinas BioPharma Holdings in a research note on Monday, June 26th.

Shares of Matinas BioPharma Holdings (NASDAQ:MTNB) remained flat at $1.36 during trading on Thursday. The company had a trading volume of 167,204 shares. The firm’s 50-day moving average price is $1.54 and its 200-day moving average price is $2.55. The stock’s market capitalization is $125.08 million. Matinas BioPharma Holdings has a 12 month low of $0.67 and a 12 month high of $3.99.

Matinas BioPharma Holdings (NASDAQ:MTNB) last announced its earnings results on Tuesday, August 8th. The company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.02 million. Matinas BioPharma Holdings had a negative net margin of 30,034.20% and a negative return on equity of 1,227.85%. Equities analysts expect that Matinas BioPharma Holdings will post ($0.26) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/10/roth-capital-analysts-give-matinas-biopharma-holdings-inc-mtnb-a-9-00-price-target.html.

A number of large investors have recently made changes to their positions in the stock. Spark Investment Management LLC bought a new position in Matinas BioPharma Holdings during the first quarter worth about $105,000. Alps Advisors Inc. bought a new position in Matinas BioPharma Holdings during the second quarter worth about $139,000. Schwab Charles Investment Management Inc. bought a new position in Matinas BioPharma Holdings during the second quarter worth about $152,000. Segantii Capital Management Ltd bought a new position in Matinas BioPharma Holdings during the first quarter worth about $166,000. Finally, KCG Holdings Inc. bought a new position in Matinas BioPharma Holdings during the first quarter worth about $193,000.

About Matinas BioPharma Holdings

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.